A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 40
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : sPD-L1
Long Form : soluble PD-L1
No. Year Title Co-occurring Abbreviation
2020 Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. IC, M-MDSCs, MCs, OC, OS, PD-L1, TC
2020 ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. ---
2020 Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. HR, NSCLC, OS, PD-L1, PFS
2020 Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. CTLA, ICIs, OS, PD, PD-L1
2020 Interferon-gamma induced PD-L1 expression and soluble PD-L1 production in gastric cancer. GC, IFN, PD-L1
2020 Maternal soluble PD-1 levels are significantly increased in women with preeclampsia. PD-1, sPD-1
2020 Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. AFP, DFS, HCC, HR, mPD-L1, OS, PD-L1, RFS
2020 Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. OS, PCNSL, PD-1, PD-L1, PFS
2020 Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. dNLR, ICIs, IeffS, LIPI, NSCLC, PB
10  2020 Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. EGFR-TKIs, HR, NSCLC, ORR, PD-L1, PFS
11  2020 Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. ICI, NSCLC
12  2020 The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. CSF, ELISA, HCs
13  2020 The prognostic role of soluble transforming growth factor-beta and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. BTC, HR, sTGF-beta
14  2020 Trophoblast-secreted soluble-PD-L1 modulates macrophage polarization and function. PD-L1
15  2019 Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. ELISA, Exo-PD-L1, IHC, NSCLC, NTA, TEM, TPS
16  2019 Identification of programmed cell death 1 and its ligand in the testicular tissue of mice. IF, PD-1, PD-L1
17  2019 Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings. Ex-TFG, LOD, LSPR, PD-L1
18  2019 Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. ICIs, PD-L1
19  2019 Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study. ELISA, NPC
20  2019 Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit. AUC, ICU, PD-1, PD-L1, sPD-1
21  2019 Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. CI, DFS, GC, HR, OS, PD-L1
22  2019 Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. L2A
23  2019 Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. OSA, PD-L1, SLN
24  2018 Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients. HNSCC, MFI
25  2018 Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism. PD-1, sPD-L2, VHF
26  2018 Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. ---
27  2018 Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients. CR, DLBCL, PD-L1, PR
28  2018 Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. IPF
29  2018 Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. HRs
30  2017 High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. PD-L1
31  2017 Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients. AR, ARIA, PD-L1
32  2017 Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. NNKTL
33  2017 Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. PD-L1
34  2017 sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis. AP, PD-1, PD-L1
35  2016 Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis. CE, IL, PD-1, PD-L1, sPD-1, sPD-1, Th
36  2016 Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. GC, PD-L1
37  2016 Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis. cITP, HCs, ITP, ndITP, PD, PD-1, PD-L1, sPD-1
38  2015 PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer. NSCLC
39  2015 [Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications]. OSCC, OSCC, PD-1, PD-L1, sPD-1
40  2013 Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. ACS, AGEs, PBMCs, PD-1, PD-L1